首页> 美国卫生研究院文献>The Journal of Clinical and Aesthetic Dermatology >United States Food and Drug Administration Product Label Changes
【2h】

United States Food and Drug Administration Product Label Changes

机译:美国食品药品监督管理局产品标签变更

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Once a drug has been approved by the United States Food and Drug Administration and is on the market, the Food and Drug Administration communicates new safety information through product label changes. Most of these label changes occur after a spontaneous report to either the drug manufacturing companies or the Food and Drug Administration MedWatch program. As a result, 400 to 500 label changes occur every year. Actinic keratosis treatments exemplify the commonality of label changes throughout the postmarket course of a drug. Diclofenac gel, 5-fluorouracil cream, imiquimod, and ingenol mebutate are examples of actinic keratosis treatments that have all undergone at least one label revision. With the current system of spontaneous reports leading to numerous label changes, each occurrence does not necessarily signify a radical change in the safety of a drug.
机译:一旦药物获得美国食品和药物管理局的批准并投放市场,食品和药物管理局就会通过更改产品标签传达新的安全信息。这些标签更改中的大多数发生在自发给药品制造公司或食品药品监督管理局MedWatch计划的报告之后。结果,每年发生400至500个标签更改。光化性角化病治疗例证了整个上市后过程中标签变化的普遍性。双氯芬酸凝胶,5-氟尿嘧啶霜,咪喹莫特和甲磺酸丁二醇酯是光化性角化病治疗的实例,这些治疗都经历了至少一次标签修订。在当前的自发报告系统导致大量标签变更的情况下,每次发生都不一定表示药物安全性的根本改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号